The most comprehensive analysis of gene dependencies in cancer cells to date has identified 370 “highly enriched” drug targets in defined molecular backgrounds. This latest iteration of the Cancer Dependency Map, published in Cancer Cell, Jan. 11, 2024, builds on an earlier version published in 2019, which was based on 324 cell lines. Read More
Cellular senescence is a state of terminal cell cycle arrest that is being increasingly explored for its role in cancer therapeutics. Researchers from Ocean University of China reported on AS-1041, an anthraquinone compound derived from the marine compound Aspergiolide A, designed to be used against leukemia due to its pro-senescence effect. Read More
Exevir Bio BV has released new data demonstrating that its antibodies are highly potent in neutralizing currently circulating COVID-19 omicron variants.
Investigators from Proqr Therapeutics NV have tested their product QR-1011, an antisense oligonucleotide designed to correct splicing abnormalities within the ABCA4 gene that affect protein expression levels, in Stargardt disease. Read More
Researchers from Hefei University and Anhui Medical University have reported the discovery of novel nitric oxide (NO) inhibitors as anti-inflammatory agents for the treatment of acute colitis. Read More
Basilea Pharmaceutica Ltd. has entered into an asset purchase agreement with Spexis AG for a preclinical program of antibiotics from a novel class, targeting gram-negative bacteria, including multidrug-resistant strains. Read More
Ensem Therapeutics Inc. has disclosed quinazoline derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Proabtech Co. Ltd. investigators have published findings from the preclinical characterization of PAT-101, a novel recombinant human albumin (rHA)-conjugated urate oxidase (Uox) variant, being developed for the treatment of gout. Read More
Syntheticgestalt Ltd. and Enamine Ltd. have begun a joint effort to create a suite of artificial intelligence (AI) models that will enable the generation of synthetically accessible biologically active compounds with optimized physicochemical and ADME/Tox properties. Read More
University of Ottawa has synthesized ferroptosis inhibitors reported to be useful for the treatment of cancer, diabetes, myocardial infarction, amyotrophic lateral sclerosis, sepsis, shock, transplant rejection and Alzheimer’s dementia. Read More
Actelion Pharmaceuticals Ltd. has identified PDGFR inhibitors reported to be useful for the treatment of pulmonary arterial hypertension (PAH). Read More
Malaria cases increase at a slow but continued rate. There is a vital need for new antimalarial treatments able to overcome drug resistance for a more sustained control of the disease. Read More
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche, Inc. have described fluorescent probes acting as monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for diagnostic imaging of MAGL. Read More
Synthesis and optimization of several series of G-protein coupled receptor 183 (GPR183) antagonists at Immunophage Biomedical Co. Ltd. led to the discovery of a lead candidate with promising potency (IC50=31.3 nM), reduced hERG inhibition and improved aqueous solubility. Read More
